HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
What's Up With These Ridiculous Stock Gains?

Steve Reitmeister didn't want me to tell you this. He felt that one strategy's performance stands out so much that... Read on >>
Quote:
Login Free Membership
Search:

 
Analyst Blog  

Medtronic Keeps Growing

July 01, 2009 | Comments: 0
Recommended this article (1)
MDT | STJ | BSX
Print    Share

Medtronic Inc. (MDT - Analyst Report) recently announced that its wholly-owned subsidiary, Physio-Control Inc., has received 510 (k) approval from FDA (Food and Drug Administration) for its next-generation LUCAS Chest Compression System, LUCAS 2.

The device was manufactured by Jolife AB, a company specializing in developing and manufacturing the LUCAS Chest Compression System, and distributed exclusively in the U.S. by Physio-Control under an agreement with Jolife. LUCAS 2 also received the CE Mark in Europe and marketing approval in Canada a few days ago. Medtronic expects to start marketing the device in the U.S. this fall. Medtronic is one of the world's leading medical technology companies, specializing in implantable and interventional therapy devices and products.

LUCAS 2 is an automated, battery-powered chest compression device that gives consistent, uninterrupted compressions to patients in cardiac arrest. This facilitates the return of spontaneous blood circulation in patients. The battery is Lithium Ion that can operate up to 45 minutes. Furthermore, the device has Smart Restart functionality that allows the battery to be replaced even in operation. This enables lower downtime and saves time for medical personnel. The device also offers new features like alerts and pauses to aid ventilation during compressions.

The new device adds to Medtronic's ever-increasing portfolio. This will help the company to improve its topline and move ahead of its nearest competitors, St. Jude Medical Inc. (STJ - Analyst Report) and Boston Scientific Corp. (BSX - Analyst Report). The company recently reported its fiscal 2009 results with revenue of approximately $14.6 billion, an increase of roughly 8% over last year. As such, our recent report has a 'Buy' recommendation on Medtronic.


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Nov 26, 2009 08:43 am ET
DJIA 10464.4  30.69 0.29%
NASD 2176.05  6.87 0.32%
S&P 500 1110.63  4.98 0.45%
Sponsored Links